Osteoarthritis Treatment - COX-2 Inhibitors
Celecoxib (CelebrexTM)
Abstract 1257 Celecoxib, A COX-2 Specific Inhibitor, is Associated with a Lower Incidence of Serious Upper Gastrointestinal (UGI) Events in Arthritis Patients Than Comparator NSAIDS
JL Goldstein, NM Agrawal, F Silverstein, RC Hubbard, W Zhao, GS Geis Chicago, IL, Durham, NC, Seattle, WA, Skokie, IL
Geis etal assessed the incidence of serious upper gastrointestinal (UGI) events in 14 controlled, double-blind trials involving a total of 11, 008 rheumatoid arthritis and osteoarthritis patients. Trials ranged from 2 to 24 weeks and patients received either placebo (n=1864), celecoxib (25 to 400 mg BID; n=6376) or a comparator NSAID (naproxen 500 mg BID, diclofenac 50-75 mg BID, or ibuprofen 800 mg TID; n=2768). 11 of 101 potential UGI events were judged to be clinically significant, ie. perforation, bleeding, and gastric outlet obstruction.
